This page is available in multiple languages
Select Language

Più Medical lists on Euronext

Back

  • 61st listing on Euronext in 2025
  • The company raised €13.3 million
  • Market capitalisation at IPO is €38.1 million

Milan – 20 November 2025 – Euronext today congratulates Più Medical on its listing on Euronext Growth Milan.

Più Medical is committed to developing a new pharmacy model based on the integration of health, prevention, and wellbeing. Through an industrial project that combines technological innovation, local presence, and a people-centred approach, Più Medical aims to redefine the role of the Italian pharmacy, transforming it into a modern, accessible ecosystem focused on community wellbeing. The company’s goal is to build a scalable, sustainable model with a high social impact.

The listing of Più Medical represents Euronext’s 61st listing this year. In the placement phase, Più Medical raised €13.3 million (including €1.6 million from the potential exercise of the greenshoe option). 
The free float at the time of admission is 18.11% (22.44% million assuming full exercise of the greenshoe option) and the market capitalisation at IPO amounts to €38.1 million.

Stefano Maroni, CEO of Più Medical, said: “Our listing on Euronext Growth Milan marks a key milestone for Più Medical and for the implementation of our industrial vision. We are creating places where health is not only dispensed, but managed, monitored and continuously improved through technology and proximity. Più Medical is not a pharmacy chain, but an integrated platform for health, prevention and longevity, placing people at the heart of a new approach to care.”

Più Medical

Fabrizio Maroni, Executive Chairman, Stefano Maroni, CEO e Fabio Giordano, CFO

About Più Medical

Più Medical is a company committed to developing a new pharmacy model based on the integration of health, prevention, and wellbeing. Through an industrial project that combines technological innovation, local presence, and a people-centred approach, Più Medical aims to redefine the role of the Italian pharmacy, transforming it into a modern, accessible ecosystem focused on community wellbeing. The goal is to build a scalable, sustainable model with a high social impact.

CONTACTS  

ANALYSTS & INVESTORS – ir@euronext.com 
Investor Relations Judith Stein  +33 6 15 23 91 97
MEDIA – mediateam@euronext.com 
Europe    Andrea Monzani  +33 1 7048 24 45
Sandra Machado  +351 917 776 897
Belgium  Marianne Aalders  +32 26 20 15 01 
France, Corporate  Flavio Bornancin-Tomasella +33 1 70 48 24 45 
Ireland Catalina Augspach +39 02 72 42 62 13 
Italy Ester Russom  +39 02 72 42 67 56 
The Netherlands  Marianne Aalders  +31 20 721 41 33 
Norway Cathrine Lorvik Segerlund +47 41 69 59 10 
Portugal Sandra Machado  +351 91 777 68 97
     
Download the press release

Press Release Footer

About Euronext 
Euronext is the leading European capital market infrastructure, covering the entire capital markets value chain, from listing, trading, clearing, settlement and custody, to solutions for issuers and investors. Euronext runs MTS, one of Europe’s leading electronic fixed income trading markets, and Nord Pool, the European power market. Euronext also provides clearing and settlement services through Euronext Clearing and its Euronext Securities CSDs in Denmark, Italy, Norway and Portugal.
As of September 2025, Euronext’s regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal host over 1,700 listed issuers with €6.5 trillion in market capitalisation, a strong blue-chip franchise and the largest global centre for debt and fund listings. With a diverse domestic and international client base, Euronext handles 25% of European lit equity trading. Its products include equities, FX, ETFs, bonds, derivatives, commodities and indices.
In November 2025, Euronext successfully acquired a majority stake in the Athens Stock Exchange (ATHEX), further expanding its footprint and strengthening its pan-European market infrastructure.

For the latest news and resources, please visit the Media Centre. 
Follow us on X (x.com/euronext) and LinkedIn (linkedin.com/company/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2025, Euronext N.V. - All rights reserved.